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ZOONOSES: an import risk for disease emergence
Infectious organism

Human pathogen

Zoonoses

Emerging diseases

(N=1709)

(N=832)

(N=156)

Viruses/Prions

507 (30%)

183 (22%)

64 (41%)

Bacteria/Rickettsia

541 (32%)

250 (30%)

48 (31%)

Fungi

309 (18%)

83 (10%)

16 (10%)

Helminths

286 (17%)

275 (33%)

9 (6%)

Protozoa

60 (3%)

41 (5%)

19 (12%)

Taylor, L.H. and Woolhouse, M.E.J., Int. Conf. Emerg. Infect. Diseases
Altanta, USA, 2000
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Infectious diseases: Human-Animal Interface
• Animals have been, are and will constitute an important
source of infectious diseases for humans:
− About half of the human pathogens are zoonotic and
9% are emerging
− The three most devastating pandemics in history
were zoonotic (Plague, Spanish Influenza, HIV/AIDS)

− About 75% of the recent emerging pathogens are
zoonotic (WNV, SARS, Nipah/Hendra, ...)
• Overall, zoonotic pathogens are more than 3 times
more likely to be associated with emerging diseases
than non-zoonotic pathogens.
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Transmission
• Zoonotic transmission includes:

– Wildlife reservoirs transmitting directly to humans:
rabies, West Nile virus…
– Transmission from a wildlife reservoir to humans via
domestic animals: influenzas, rabies, Hendra and
Nipah, brucellosis, tuberculosis

– Transmission to humans via the Food chain (Food
Safety): salmonella, E. coli O157,

(Lloyd-Smith J.O. et al. (2009) Science 326: 1362-1367
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Diagram of zoonotic transmission dynamics

J. O. Lloyd-Smith et al., Science 326, 1362-1367 (2009)
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Emergence of new agents
• Increased global travel: e.g. influenza’s –
Avian/swine
• Relaxation of veterinary regulations: e.g. EIV
outbreak in Australia in 2007
• Unpredictable effects of climate change:
Bluetongue virus outbreak in Europe
• Urbanization and change in animal husbandry:
HSF, PRRS and PCV-2 in swine
• The threat of intentional release…
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The example of Nipah/Hendra
• Hendra and Nipah viruses are newly discovered zoonotic viruses first
isolated from outbreaks in Australia (1994) and Malaysia (1998)
• The viruses are closely related and member of the paramyxoviridae
family, genus Henipahvirus.
• The viruses cause severe disease in a variety of animal species,
including humans, horses, pigs, dogs and cats

• Both viruses are classified as BSL-4
pathogens and Nipah is on the list of
select agents by the USDA

Eaton et al, 2006. Nature Reviews Microbiology
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Hendra outbreaks
• In September 1994, an outbreak of acute respiratory
disease occurred in a group of horses outside Brisbane
• 20 horses affected: 14 died (6 euthanized)
• Horses were tachypnoeic, tachycardic, ataxic, frothy
nasal discharge, collapse – 7 deaths within 12 hours,
(10 < 36 hours)
• Two people nursing the index case became infected, 1
died
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Hendra outbreaks
• Since 1994, Hendra has caused a few sporadic outbreaks in
Australia, ie a total of 14 reported outbreaks involving ~40
horses and 7 humans
− Case-fatality rate in horses: 80%
− Case-fatality rate in humans: 57%. One patient presenting
relapsed encephalitis long after the initial infection
• Equine cases occur mainly late winter/spring. Horse to horse
transmission is not easy
• All human cases associated with close contact with affected
horses (endoscopy, treating, nursing or post-mortem
examination). Extremely low risk handling normal horses
• No human-to-human transmission reported
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Nipah outbreaks
• Nipah emerged in 1998 in Malaysia and caused widespread
panic because of the high mortality rate (40%) in people and
the inability to control the disease initially.
• Pigs were the apparent source of infection among most
human cases (farmers, abattoir workers). Pigs were
frequently asymptomatic (silent spreaders)
• Subsequent outbreaks in Malaysia, India and Bangladesh in
2000-2008
• Human case-fatality rate 40-75%
• Human-to-human transmission of Nipah virus and no obvious
direct link to infected livestock reported in later outbreaks.
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Nipah Field Investigations - Malaysia
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The Impact of the Outbreak
• Limited in geographic extension, but….

• The Malaysian outbreak caused considerable
social disruptions and tremendous economic
loss to an important pig industry.
–
–
–
–

Nearly 1 million pigs culled (58 M$)
Loss of the capital infrastructure on farms
Loss of employment - 36,000 jobs
Loss of export income - 120 M$
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Where did the virus come from?
• Pteropid bats (fruit bats) are believed to be the natural
reservoir hosts. Different bat species for Nipah and Hendra

• Seroprevalence varies between bat colonies (2–50%).
Suggests non-lethal infection in bats
• Detected in bat secretions (abortions & urine)
• No definitive data on bat-to-bat spread
• Spill-over transmission to pigs/horses is likely
to occur through contaminated water and feed
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Global Distribution of fruit bats

Courtesy: CSIRO
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Distribution of outbreaks and bat populations
Cairns 1999: 1 horse 2004: 1 horse, 1 human
Townsville 2004: 1 horse
Cannonvale 2008: 1 horse
Mackay 1994: 1 horse, 1 human
Rockhampton 2009: 3 horses, 1 human
Peachester 2006: 1 horse 2007: 1 horse
Brisbane 1994: 20 horses, 2 humans
Brisbane 2008: 5 horses, 2 humans
Murwillambah 2006: 1 horse

• Antibody to Hendra has been detected in all 4 species of fruit bats
indigenous to Australia. Equine cases occur mainly late winter/spring
Associated with bat breeding season?
• Influx of more than 130.000 bats into Victoria since early 2010
attributed to wet weather conditions in Queensland
Courtesy. Gilkerson
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Transmission cycle
Hendra virus

Spill over

Ro< 1
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Transmission cycle
Nipah virus

Spill over

Spill over

Ro>1

Ro>1
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Management of the disease
• The following counter measurements are important
– Surveillance: first line of defense. Very often relies on
reporting of clinical disease in populations at risk, which is
not very reliable
– Culling: stop spread of virus
– Vaccination: no commercial vaccines are available today
– Diagnosis: stall-site (point-of-care) diagnostic tests are
needed but not yet available

Vaccine Technology III, Mexico, 2010

7

Vaccination
• Vaccination remains a primary method for
the effective prevention and control of
Nipah/Hendra
• The role of Manufactures for a timely
supply of affordable and fit-for–
purpose vaccines is pivotal
• Key to risk management is communication
and co-operation through every sector of
the industry.
• Several initiatives are ongoing….
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Challenges and constraints
• The development of a human vaccine is likely to be expensive and
long range making it uneconomical for any pharmaceutical
company to undertake. Veterinary vaccines should be considered
• Competition for assigned R&D resources
• Need for high containment facilities to develop and produce
vaccine

• Scale up and transfer to Manufacturing
• Availability of BSL4 animal test facilities for testing of vaccines
The use of well characterized vaccine platforms will
alleviate some of these issues
Vaccine Technology III, Mexico, 2010
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Potential available platforms
Replicating vectors

Non replicating vectors

Viruses

Viruses

• Poxviruses (vaccinia)
• Adenoviruses
• Herpes viruses (HVT)

Bacteria

• Mycobacteria (BCG)
• Salmonella

DNA vectors

• (Avi)Poxviruses (ALVAC)
• Adenoviruses (E1 del)
• Herpesviruses (gD del)

DNA vaccines

• Plasmids (Melanoma; WNV)
• Linear expression cassettes

• Replicons

Expression systems

RNA vectors

• Plant expression
• Peptides

• Replicons

• Baculovirus (PCV-2)

Technologies having at least one example of registered vaccine
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The use of ALVAC as a vector
– The canarypox virus vector originates from an
attenuated vaccine strain for canaries
– Large genome, easily manipulated and
genetically stable
– Real technology platform used for commercial
vaccines in dogs, cats, ferrets and horses and has
has potential in humans
– Non replicative vector in mammals

‘’Single hit infection’’
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Vector virus
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After vaccination the vector infects and instructs the cell
to produce the protective proteins which in turn are
presented to the immune system in a way that closely
mimics natural infection (authentic expression). The
vaccine induces both B and T cell immunity.
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ALVAC is a true technology platform
R&D
• Rapid generation of new constructs (strong expertise)
• No handling of dangerous pathogens (WNV, H5N1,
NiV..) through the use of synthetic genes

Manufacturing
• Same manufacturing process for all recombinants:
simple process with high batch-to-batch consistency
which is easy to scale up
• Standardized batch release test

Regulatory
• Known technology.
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ALVAC: a commercial success
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Nipah vaccine candidates
• Several vaccine platforms have been tested successfully
for efficacy in animal models
– Recombinant vaccinia vaccine expressing G or F of NiV
virus (Guillaume et al. J. Virol. 78, 2004). Regulatory
acceptance?
– Subunit vaccine containing soluble G protein of NiV
purified from recombinant vaccinia infected cells
(Mungall et al. J. Virol. 80, 2006). Scalability?
– Recombinant canarypox (ALVAC) vaccine expressing G
or F of NiV virus
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Proof of concept ALVAC-NiV constructs
• Pigs were vaccinated twice IM at 14 days interval and
challenged on D28 by intranasal inoculation of NiV (2.5
x 10E5 PFU)
V1

V2

Ch

0

14

28

Treatment groups (4 pigs per group)
1 ALVAC F
2 ALVAC G
10E8 PFU/construct
3 ALVAC G + F
4 Controls
ALVAC-F

ALVAC-G

Vaccine Technology III, Mexico, 2010

ALVAC G + F

1
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Virus Isolation Post-Challenge (PFU/ml)
C

dpi

#39

NW

480

PS

740

#40

#41

1/2

3/4

NW

20

60

PS

10

20

NW

100

10

PS
#42

6/7

NW

60
60

C

Brain

Olfactory
Bulb

Trigeminal
ganglion

Turbinate

Trachea

Submand
LNN

Bronch.
LNN

#39

0

1.25

1.25

1025

420

200

84

#40

5

nd

713

120

80

15

12.5

#41

12.5

0

0

2.5

16

nd

0

#42

0

nd

2625

45

0

0

0

PS

• Vaccination led to the development of
high antibody levels
• Vaccination with ALVAC-NiV prevented
virus replication and virus shedding
• Combined vaccination with both G and F
induced the best protection
Courtesy Wiengartl
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Conclusions
• Zoonotic pathogens constitute an important risk for emerging
diseases in man
• Vaccination, together with management measures, remains the
primary method for the effective prevention and control of
emerging diseases
• Well established vaccine platforms will facilitate development and
reduce time to market
• The example of Nipah/Hendra shows that effective control is the
shared responsibility of Governments, Industry and stake holders
• An effective vaccine against Nipah/Hendra is within reach….
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